ClinicalTrials.gg
RecruitingNCT04986293SISTERUpdated May 4, 2026

CPAP or BiPAP for Motion Mitigation During Radiotherapy

An interventional study of CPAP in Radiotherapy Side Effect, NSCLC and Esophageal Cancer, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

When using highly conformal radiotherapy techniques, such as proton therapy, a controlled breathing pattern and a minimal breathing amplitude could greatly benefit the treatment of mobile tumors. This reduction in tumor motion may be achieved with the use of a ventilator that is able to regulate and modulate the breathing pattern. CPAP provides a constant level of positive airway pressure. Compared to spontaneous breathing, the use of CPAP increased lung volume and can result in a significant decrease in tumor movement and a significant decrease in both mean lung and mean heart radiation dose. These results were found in patients treated for limited stage disease, it is not clear if this approach is feasible for patients with more advanced stage of disease that undergo radiotherapy with curative intent.

With Bilevel Positive Airway Pressure (BiPAP), tidal volume excursions are determined by the pressure difference between the set inspiratory positive airway pressure (IPAP) and the set expiratory positive airway pressure (EPAP). This mode of ventilation increases lung volume comparable to CPAP, but also to control tidal volumes and breathing frequency. However, BiPAP has never been studied in the setting of motion mitigation during radiotherapy and BiPAP might be more difficult to adjust to for patients compared to CPAP. Therefore, the current study is proposed to evaluate whether or not CPAP or BiPAP is of benefit in patients that undergo radiotherapy for larger intra-thoracic tumor volumes.

Read the detailed description

The study will follow a 2-step approach.

First (Phase 1, n=10), the feasibility of short-term use of CPAP and BiPAP and its effects on (regional) lung volumes, tidal volumes and breathing frequency will be investigated in patients with intra-thoracic tumors who are planned for radiotherapy. This is necessary to select the best setting of CPAP or BiPAP with which minimal tumor motion is expected (and that is feasible for the patient).

In the second phase (n=21), the particular setting found in fase 1 is investigated: weekly repeated radiotherapy planning (4D) CT scans with and without CPAP/BiPAP will be aquired to evaluate the influence on tumor motion and dose to the target and organs at risk. Radiotherapy will be deliverd according to local protocol without the use of CPAP/BiPAP.

02

Conditions studied

  • Radiotherapy Side Effect
  • NSCLC
  • Esophageal Cancer
  • Malignant Lymphoma

Keywords

  • BiPAP
  • CPAP
  • Mechanical ventilation
03

In context

Radiation Injuries

328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.

This study's planned enrollment of 31 is below the median of 72 across 216 interventional studies indexed under Radiation Injuries.

Browse Radiation Injuries studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Stage III/IV (N)SCLC, esophageal cancer or malignant lymphoma that will be treated with curative intent
  • WHO 0-2.
  • Written

Exclusion criteria

Exclusion Criteria:

  • Facial deformations so that facial mask is impossible to fit
  • Noncompliance with any of the inclusion criteria.
  • Planned for radiotherapy with fraction dose ≥3 Gy.
  • Severe heart failure (\<30%)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Interventions

  • DeviceCPAP

    Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator

    Also known as: BiPAP

06

What researchers measure

Primary outcomes

  1. Lung volume changes induced by the use of mechanical ventilation

    The primary objective is to evaluate the lung volume changes (in cm3) induced by the use of mechanical ventilation

    Time frame: 2-3 hours of measurement (only once)

Secondary outcomes

  1. Feasibility of mechanical ventilation

    Feasibility is expressed as a score (using a Visual Analoge Scale)

    Time frame: once every week up to a maximum of 5 consecutive weeks (depending on the duration of the course of radiotherapy)

  2. Feasibility of mechanical ventilation

    Feasibility is expressed as the duration (minutes) the participant can undergo mechanical ventilation

    Time frame: once every week up to a maximum of 5 consecutive weeks (depending on the duration of the course of radiotherapy)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jul 2027, 73 months after the start.

Of 69 non-industry interventional studies with no phase under Radiation Injuries, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 73 months is above that.

Counting every sponsor, half of 72 studies reached it within 43 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2021
First posted
Aug 2, 2021
StartActual
Jun 1, 2021
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04986293
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Jun 1, 2021
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 4, 2026

Study contacts

Robin Wijsman
Contact
info@rt.umcg.nl
+31503612711
J. Elshof
Contact
j.elshof@umcg.nl
+31503611036
Robin Wijsman
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion